An interventional study of Bone marrow and blood samples and Bone marrow sample in Chronic Myelomonocytic Leukemia, sponsored by Centre Hospitalier Universitaire de Nice. Not yet recruiting at 1 site in France. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Basic science
MAC-AGE is a single-center study designed to characterize bone marrow macrophages in patients with chronic myelomonocytic leukemia (CMML) and to compare them with macrophages from age-matched controls undergoing elective total hip arthroplasty. Phenotypic, transcriptional and functional analyses will be performed using spectral/multiparametric flow cytometry, single-cell RNA sequencing and ex vivo functional assays. The study aims to identify CMML-associated macrophage alterations and potential therapeutic targets within the bone marrow immune microenvironment.
329 studies on the registry are indexed under Leukemia, Myelomonocytic, Chronic; 67 are open to participants now.
This study's planned enrollment of 120 is above the median of 42 across 297 interventional studies indexed under Leukemia, Myelomonocytic, Chronic.
Browse Leukemia, Myelomonocytic, Chronic studies →Centre Hospitalier Universitaire de Nice is the lead sponsor of 709 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion criteria - Group Patients with CML
Inclusion criteria - Group Age-matched healthy controls
2 mL of additional bone marrow are collected during a planned standard-of-care sternal or iliac aspiration, together with 40 mL of additional peripheral blood during routine blood sampling.
Procedure: Bone marrow and blood samples
2 mL of bone marrow are collected from the proximal femoral metaphysis during elective total hip arthroplasty after femoral neck osteotomy, without any additional invasive procedure
Procedure: Bone marrow sample
2 mL of additional bone marrow are collected during a planned standard-of-care sternal or iliac aspiration, together with 40 mL of additional peripheral blood during routine blood sampling.
2 mL of additional bone marrow are collected during a planned standard-of-care sternal or iliac aspiration, together with 40 mL of additional peripheral blood during routine blood sampling.
Phenotypic and transcriptional differences in bone marrow macrophages between CMML patients and age-matched controls
Bone marrow macrophages will be characterized by spectral/multiparametric flow cytometry, including CD80, CD86, HLA-DR, CD163, CD206, CD209, CD200R, SIRPα and MARCO, and by targeted RT-qPCR and/or exploratory single-cell RNA sequencing. Differential macrophage populations and gene-expression programs will be compared between the two groups.
Time frame: at inclusion
Functional and immunomodulatory profile of bone marrow macrophages
Ex vivo cytokine secretion (including TNF-α, IL-10, CCL2 and TGF-β), phagocytosis of apoptotic or leukemic targets, modulation of naïve CD4+ T-cell polarization (Th1 versus Th2), and response to experimental pharmacological modulators targeting non-canonical caspase-8 and cathepsin B will be assessed and compared between groups
Time frame: at inclusion
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Myelomonocytic, Chronic→
Centre Hospitalier Universitaire de Nice